Amandeep Godara

Feb 14, 2025 | cancernetwork.com | Cristina Gasparetto |Amandeep Godara |Ken Shain |Mansi Shah

February 14, 2025By Panelists discuss how frailty assessment influences treatment decisions in patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), particularly examining the IFM2017-03 study’s evaluation of a dexamethasone-sparing approach using daratumumab plus lenalidomide in frail patients. Video content above is prompted by the following:How does frailty impact treatment outcomes in transplant-ineligible NDMM?

Feb 14, 2025 | cancernetwork.com | Cristina Gasparetto |Amandeep Godara |Ken Shain |Mansi Shah

February 14, 2025By Panelists discuss how the treatment landscape for patients with transplant-ineligible/deferred newly diagnosed multiple myeloma (NDMM) is expected to evolve, with considerations for optimizing therapeutic approaches based on emerging data from novel drug combinations and treatment strategies. Video content above is prompted by the following:How do you see the future treatment landscape for patients with transplant-ineligible/deferred NDMM? Related Content Related Content